Concept Solid Tumors

Solid Tumors

Solid tumors are remarkably diverse in their cellular origins and developmental stages. Comprehensive genomic profiling is needed for solid tumor specimens in order to capture their cellular and/or molecular heterogeneities.

Our pan-cancer gene panels for all solid tumors and cancer-type specific genetic tests can meet all your clinical needs for precision medicine.

Pan-Cancer Gene PanelsCancer-Type Specific Gene Panels

PAN-CANCER GENE PANELS

GENESEEQPRIME®

A comprehensive genomic profiling panel across all solid tumors

GeneseeqPrime® analyzes 425 cancer-related genes by next-generation sequencing. It reveals clinically actionable information for therapy selection by providing valuable insight into key oncogenic genes and drug resistance mechanisms.

WHO IS IT FOR

Patients with solid tumors seeking precision medicine

SAMPLE TYPES
Icon Tumour Tissue

Tumor tissue (FFPE block/slides, or frozen tissue)

Icon Fine Needle Biopsy

Fine needle biopsy

Icon Liquid Biopsy

Liquid biopsy (plasma and others)

Product GeneeeqPrime
Logo GeneseeqPrime

All-in-one test for 425 cancer-related genes

Icon Checked

Identifies numerous mutation types: single nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), gene fusions and large genomic rearrangements (LGR)

Icon Checked

Assesses key biomarkers: tumor mutation burden (TMB), microsatellite instability (MSI), DNA mismatch repair (MMR) genes, homologous recombination repair (HRR) genes

GeneseeqPrime® Report

Icon Item 1

Provides information for clinically actionable genomic alterations and their associated targeted therapy, both approved and in clinical trials

Icon Item 2

Evaluates TMB and MSI with the option to add the PD-L1 immunohistochemistry (IHC) test to better inform immunotherapy decisions

Icon Item 3

Predicts efficacy and toxicity of chemotherapy based on associated genetic biomarkers

Icon Item 4

Reveals potential resistance mechanism(s) to current therapies and options for alternative treatments

Icon Item 5

Assesses genetic predisposition to certain cancer types for early intervention

Contact us today to learn more about
GeneseeqPrime®

GeneseeqPrime® HRD

Comprehensively evaluates homologous recombination deficiency

GeneseeqPrime® HRD is a next-generation sequencing-based laboratory developed test that analyzes homologous recombination deficiency (HRD)-related genomic instabilities through a genome-wide analysis approach. It also detects genomic alterations in 425 cancer-relevant genes, including BRCA1/2 and other homologous recombination repair (HRR)-relevant genes.

WHO IS IT FOR

Patients with solid tumors seeking precision medicine, including PARP inhibitors selection, other targeted therapy options and immunotherapy

SAMPLE TYPES
Icon Tumour Tissue

Tumor tissue (FFPE block/slides, or frozen tissue)

All-in-one test

Icon Checked

Genome-wide HRD score by assessing loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale station transitions (LST)

Icon Checked

Genomic alterations in 425 cancer-relevant genes, including 25 HRR genes

Icon Checked

Identifies numerous mutation types: single nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), gene fusions and large genomic rearrangements (LGR)

Icon Checked

Assesses other key biomarkers: tumor mutation burden (TMB), microsatellite instability (MSI), DNA mismatch repair (MMR) genes, homologous recombination repair (HRR) genes

GeneseeqPrime®HRD Report

Icon Item 1

Evaluates HRD score and HRR-gene alterations to inform PARP inhibitors selection

Icon Item 2

Assesses TMB, MSI and dMMR with the option to add the PD-L1 immunohistochemistry (IHC) test to better inform immunotherapy decisions

Icon Item 3

Provides information for other clinically actionable genomic alterations and their associated targeted therapy, both approved and in clinical trials

Icon Item 4

Reveals potential resistance mechanism(s) to current therapies and options for alternative treatments

Icon Item 5

Assesses genetic predisposition to certain cancer types for early intervention

Contact us today to learn more about GeneseeqPrime®HRD

BRCASCAN™

A comprehensive genetic test for BRCA1/2 and other key HRR-related genes

BRCAscanTM analyzes 26 key genes in homologous recombination repair (HRR) pathways, including BRCA1/BRCA2, to inform treatment decisions such as PARP inhibitors selection and assess genetic predisposition to breast, ovary, prostate and pancreatic cancers.

WHO IS IT FOR

  • Individuals with a family history of BRCA1 or BRCA2 mutations
  • Breast cancer patients with one or more of the following conditions:
    • Early onset breast cancer diagnosed before age 45
    • Family history of breast or/and ovarian cancer
    • Triple negative breast cancer diagnosed at age 60 or younger
    • Bilateral breast cancer diagnosed at age 50 or younger with two or more primary lesions
    • HER2-negative metastatic breast cancer
    • Male breast cancer patients
  • Patients with advanced or recurrent ovarian cancer
  • Patients with hereditary breast and ovarian cancer syndrome (HBOC)
  • Patients with two or more types of cancer
  • Patients with metastatic prostate cancer
  • Patients with metastatic pancreatic cancer

SAMPLE TYPES
Icon Tumour Tissue

Tumor tissue (FFPE block/slides, or frozen tissue)

Icon Fine Needle Biopsy

Fine needle biopsy

Icon Liquid Biopsy

Liquid biopsy (plasma and others)

Product Radiotron

RADIOTRON™

Bringing precision medicine
to radiotherapy

Radiotherapy is an important modality in treating cancer patients. Radiotron™ is a 474-gene panel for all solid tumors that is upgraded from GeneseeqPrime® 425-gene panel. It has a total of 106 genes associated with radiosensitivity, radiotherapy tolerance and susceptibility to radiation-induced second cancer.

WHO IS IT FOR

Solid tumor patients seeking personalized drug and radiotherapy

SAMPLE TYPES
Icon Tumour Tissue

Tumor tissue (FFPE block/slides, or frozen tissue)

Icon Fine Needle Biopsy

Fine needle biopsy

CANCER-TYPE SPECIFIC GENE PANELS

Lung Cancer

LUNG CANCER

See Our Products
Breast Cancer And Gynecological Tumors

BREAST AND GYNECOLOGIC CANCERS

See Our Products
Urinary and Male Reproductive System Tumors

UROLOGIC CANCERS

See Our Products
Gastrointestinal Cancer

GASTROINTESTINAL CANCERS

See Our Products
Other Tumours

CENTRAL NERVOUS SYSTEM TUMORS

See Our Products
Other Tumors

OTHER TUMORS

See Our Products

LET’S ACCELERATE PRECISION CANCER CARE, TOGETHER.

Learn more about our products and services or contact us today to discuss how we can partner together.

Contact Us